Results 241 to 250 of about 90,557 (301)

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

Tumor‐Derived Exosomal piR‐hsa‐28212 Promotes Lymphatic Metastasis in Breast Cancer

open access: yesCancer Science, EarlyView.
Breast cancer–derived exosomal piR‐hsa‐28212 promotes lymphangiogenesis and lymph node metastasis by activating VEGFC/VEGFR3 signaling. It stabilizes TBX1 mRNA in lymphatic endothelial cells and METTL3 protein in tumor cells, enhancing VEGFR3 expression and VEGFC secretion.
Yafen Wang   +7 more
wiley   +1 more source

Update of germ line RUNX1 variant curation rules: version 3.1. [PDF]

open access: yesBlood Adv
Hattig Z   +7 more
europepmc   +1 more source

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics

open access: yesClinical Genetics, EarlyView.
The WHO Classification of Tumours underpins the diagnosis of neoplastic conditions. The new WHO classification of genetic tumour syndromes (GTS) provides international standards for their diagnosis. This diagram highlights the chromosomal distribution of the genes involved in the GTS covered in this classification.
Ian A. Cree   +18 more
wiley   +1 more source

A patient-derived CABIN1 mutation recapitulates features of idiopathic multicentric Castleman disease in a mouse model. [PDF]

open access: yesBlood Adv
Laczko D   +10 more
europepmc   +1 more source

Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection. [PDF]

open access: yesBlood Adv
Sudha P   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy